Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 13/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.43 |
| ▸ | ADRB2 | P07550 | 11/20 | 0.42 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.38 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL98938 | 1.00 | CHRM3 (0.43) | CHRM3CHRM2CHRM1ADRB2CHRM5 | |
| SCHEMBL98940 | 1.00 | CHRM3 (0.43) | CHRM3CHRM2CHRM1ADRB2CHRM5 | |
| SCHEMBL99947 | 0.91 | CHRM3 (0.45) | CHRM3CHRM2CHRM1ADRB2CHRM5 | |
| SCHEMBL132259 | 0.91 | CHRM3 (0.45) | CHRM3CHRM2ADRB2CHEK1 | |
| SCHEMBL100308 | 0.90 | CHRM3 (0.47) | CHRM3CHRM2CHRM1ADRB2CHRM5 | |
| SCHEMBL99016 | 0.90 | CHRM3 (0.45) | CHRM3CHRM2CHRM1ADRB2CHRM5 | |
| SCHEMBL661508 | 0.90 | CHRM3 (0.45) | CHRM3CHRM2CHRM1ADRB2CHRM5 | |
| SCHEMBL663673 | 0.89 | CHRM3 (0.44) | CHRM3CHRM2ADRB2 | |
| SCHEMBL98812 | 0.88 | CHRM3 (0.46) | CHRM3CHRM2CHRM1ADRB2CHRM5 | |
| SCHEMBL663916 | 0.88 | CHRM3 (0.46) | CHRM3CHRM2CHRM1ADRB2CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2426121-A1 | QUATERNARY AMMONIUM SALT COMPOUND | Teijin Pharma Limited (JP) | 2012-03-07 | — | — | EP | claimed |
| US-20120046467-A1 | QUATERNARY AMMONIUM SALT COMPOUNDS | TEIJIN PHARMA LIMITED (JP) | 2012-02-23 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046467-A1 | QUATERNARY AMMONIUM SALT COMPOUNDS | ADRB2, AGTR2, ADRB3 | CHRM3 9/4885CHRM2 15/4885CHRM1 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.